Mitochondrial pathobiology in Parkinson's disease and amyotrophic lateral Sclerosis

Journal of Alzheimer's Disease

Volumn 20, Issue SUPPL.2, 2010, Pages

  Martin, Lee J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenine nucleotide translocator; apoptosis; cell death; cyclophilin D; excitotoxicity; mitochondrial permeability transition pore; motor neuron; ppif voltage dependent anion channel

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; COPPER ZINC SUPEROXIDE DISMUTASE; DJ 1 PROTEIN; DYNACTIN; F BOX PROTEIN; LEUCINE RICH REPEAT KINASE 2; MITOCHONDRIAL DNA; MITOCHONDRIAL ENZYME; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NITRIC OXIDE SYNTHASE; PARKIN; PHOSPHOLIPASE A2 GROUP VI; PROTEIN BAX; PROTEIN P53; SERINE PROTEINASE OMI; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTERIOR HORN CELL; BRADYKINESIA; BRAIN MITOCHONDRION; CELL AGING; CELL DEATH; CYTOSOL; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; GAIT DISORDER; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; GLOBUS PALLIDUS; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION SWELLING; NERVE CELL DEGENERATION; NERVE CELL EXCITABILITY; NERVE DEGENERATION; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; RIGIDITY; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; TREMOR;

EID: 77956212418     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100348     Document Type: Review

References (205)

1. Zorov DB, Isave NK, Plotnikov EY, Zorova LD, Stelmashook EV, Vasileva AK, Arkhagelskaya AA, Khrjapenkova TG (2007) The mitochondrion as Janus Bifrons. Biochemistry (Moscow) 72, 1115-1126.
2. Nicholls DG (2002) Mitochondrial function and dysfunction in the cell: its relevance to aging and aging-related disease. IntlJ Biochem Cell Biol 34, 1372-1381.
3. Wallace DC (2002) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn of evolutionary medicine. Annu Rev Genet 39, 359-407.
4. Fridovich I (1995) Superoxide radical and superoxide dis-mutases. Annu Rev Biochem 64, 97-112.
5. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases. Drugs Aging 18, 685-716.
6. Mungrue IN, Bredt DS, Stewart DJ, Husain M (2003) From molecules to mammals: what's NOS got to do with it? Acta Physiol Scand 179, 123-135.
7. Beckman JS, Carson M, Smith CD, Koppenol WH (1993) ALS, SOD and peroxynitrite. Nature 364, 548.
8. Martin LJ, Liu Z (2002) DNA damage profiling in motor neurons: a single-cell analysis by comet assay. Neurochem Res 27, 1089-1100.
9. Giulini C (2003) Characterization and function ofmitochon-drial nitric-oxide synthase. Free Radic Biol Med 34, 397-408.
10. Brown GC, Borutaite V (1999) Nitric oxide, cytochrome c, and mitochondria. Biochem Soc Sym 66, 17-25.
11. Delettre C, Lenaers G, Pelloquin L, Belenguer P, Hamel CP (2002) OPA1 (Kjer type) dominant optic atrophy: a novel mitochondrial disease. Mol Genet Metab 75, 97-107.
12. Martin LJ, Al-Abdulla NA, Brambrink AM, Kirsch JR, Sieber FE, Portera-Cailliau C (1998) Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res Bull 46, 281-309.
13. Northington FJ, Graham EM, Martin LJ (2005) Apoptosis in perinatal hypoxic-ischemic brain injury: how important is it and should it be inhibited? Brain Res Rev 50, 244-257.
14. Martin LJ (2010) The mitochondrial permeability transition pore: a molecular target for amyotrophic lateral sclerosis. Biochim Biophys Acta 1802, 186-197.
15. Waldmeier PC, Zimmermann K, Qian T, Tintelnot-Blomley M, Lemasters JJ (2003) Cyclophilin D as a drug target. Curr Med Chem 10, 1485-1506.
16. Crompton M (2004) Mitochondria and aging: a role for the permeability transition? Aging Cell 3, 3-6.
17. Halestrap AP (2009) What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 46, 821-831.
18. Bernardi P, Krauskopf A, Basso E, Petronilli V, Blalchy-Dyson E, Di Lisa F, Forte MA (2006) The mitochondrial permeability transition from in vitro artifact to disease target. FEBSJ 273, 2077-2099.
19. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Indicence of Parkinson's disease: variations by age, gender and race ethnicity. Am J Epidemol 157, 1015-1022.
20. Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79, 368-376.
21. Lowe J, Lennox G, Leigh PN (1997) Disorders of movement and system degeneration. In Greenfields Neuropathol-ogy, Graham DI, Lantos PL, eds. London: Arnold, pp. 281366.
22. Braak H, Del Tredici K, Rub U, d Vos RAI, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197-211.
23. Martin LJ (2002) Neurodegenerative disorders of the human brain and spinal cord. In Encyclopedia of the Human Brain; Ramachandran VS, ed. Elsevier Science, Volume 3, pp. 441463.
24. Goedert M (2001) Alphα-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2, 492-501.
25. Schapira AHV (2006) Etiology ofParkinson's disease. Neurology 66 (Suppl 4), S10-S23.
26. Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCul-lough ML, Calle EE, Schwarzchild MA, Thun MJ (2006) Pesticide exposure andriskfor Parkinson's disease. AnnNeu-rol 60, 197-203.
27. Shimohama S, Swada H, Kitamura, Y, Taniguchi T (2003) Disease model: Parkinson's disease. Trends Mol Med 9,360365.
28. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropou-los T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
29. Singleton, AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) Alphα-synuclein locus triplication causes Parkinson's disease. Science 302, 841.
30. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Browstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Poly-meropoulos MH (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
31. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259.
32. Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiya-ma H, Yoshino H, Asahina M, Kobayashi S, Hassin-Baer S, Lu CS, Ng AR, Rosales PL, Shimizu N, Toda T, Mizuno Y, Hattori N (2004) Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol 56, 424-427.
33. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
34. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert A, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160.
35. Paisan-Ruz C, Jain S, Whitney Evans E, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Martnez-Gil A, Khan N, Johnson J, Ruiz Martinez J, Nicholl D, Marti Carrera I, Saenz Peoa A, de Silva R, Lees A, Mart-Masso JF, Perez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
36. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessi J, Pfeiffer RF, Patenge N, Carballo Carbajal I, Vieregge P, As-mus F, Muller-Myhsok B, Dickson DW, Meitinger T, Storm TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607.
37. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat A-L, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38, 1184-1191.
38. Lesuisse C, Martin LJ (2002) Long-term culture of mouse cortical neurons as a model for neuronal development, aging, and death. J Neurobiol 51, 9-23.
39. Maroteaux L, Campanelli JT, Scheller RH (1988) Synucle-in: a neuron-specific protein localized to the nucleus and presynaptic nerve terminals. J Neurosci 8, 2804-2815.
40. Murphy DD, Rueter SM, Trojanowski JQ, Lee VMY (2000) Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20, 3214-3220.
41. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Sudhof TC (2004) Double knockout mice for a-and ft-synucleins: effect on synaptic functions. Proc Natl Acad Sci U SA 101, 14966-14971.
42. Gurevicine I, Gurevicius K, Tanila H (2007) Role of α-synuclein in synaptic glutamate release. Neurobiol Dis 28, 83-89.
43. Liu S, Fa M, Ninan I, Trinchese F, Dauer W, Aranico O (2007) α-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CAMKII. Eur J Neurosci 25, 3583-3596.
44. Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH (2005) Neural activity control the synaptic accumulation of α-synuclein. J Neurosci 25, 10913-10921.
45. Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudholf TC (2005) α-synuclein cooperates with CSPa in preventing neurodegeneration. Cell 123, 383-396.
46. Gallardo G, Schluter OM, Sudhof TC (2008) A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aft peptides. Nat Neurosci 11, 301-308.
47. Serpell LC, Berriman J, Jakes M, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic alpha synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA 97, 4897-4902.
48. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000) Acceleration of oligomerization, not fibrilization, is a shared property ofboth alphα-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97, 571-576.
49. Caughey B, Lansbury PT (2003) Protofibrils, pores, fibril, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26, 267-298.
50. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mal-lory M, Wong J, Takenouchi T, Hashimoto M, Masliah E (2000) Alphα-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157, 401-410.
51. Junn E, Mouradian MM (2002) Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 320, 146-150.
52. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH (2000) Expression of mutant alphα-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9, 2683-2689.
53. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee WM-Y (2002) Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein. Neuron 34, 521-533.
54. Giasson BI, Duda JE, Murray IVJ, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM-Y (2000) Oxidative damage linked to neurodegeneration by selective alphα-synuclein nitration in synucleinopathy lesions. Science 290, 985-989.
55. Ischiropoulos H (2003) Oxidative modification of alphα-synuclein. Ann NY Acad Sci 991, 93-100.
56. Wilkinson KD, Lee KM, Deshpande S, Duerken-Hughes P, Boss JM, Pohl J (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl terminal hydrolase. Science 246, 670-673.
57. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67, 425-479.
58. Lansbury PT Jr, Brice A (2002) Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr Opin Cell Biol 14, 653-660.
59. McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shahid-haran P, Jennert P, Olanow CW (2002) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 81, 301-306.
60. Imai Y, Takahashi R (2004) How do Parkin mutations result in neurodegeneration? Curr Opin Neurobiol 14, 384-389.
61. Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, Elibol B, Brookes AJ, Yamamura Y, Kobayashi T, Wang M, Yoritaka A, Minoshima S, Shimizu N, Mizuno Y (1998) Point mutations (Thr240Arg and Gln311Stop) in the Parkin gene. Biochem Biophys Res Commun 249, 754-758.
62. Beilina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, Cookson MR (2005) Mutations in PTEN-induced putative kinase 1 associated with recessive parkin-sonism have differential effects on protein stability. Proc Natl Acad Sci USA 102, 5703-5708.
63. Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, Casari G (2005) Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14, 3477-3492.
64. Unoki M, Nakamura Y (2001) Growth-suppressive effects of BPOZ and RGR2, two genes involved in the PTEN signaling pathway. Oncogene 20, 4457-4465.
65. Taymans J-M, Van den Haute C, Baekelandt V (2006) Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 98, 951-961.
66. Weihofen A, Thomas KJ, Ostazewski BL, Cooksen MR, Selkoe DJ (2009) Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 48, 2045-2052.
67. Deng H, Jankovic J, Guo Y, Xie W, Le W (2005) Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun 337, 1133-1138.
68. Marongiu R, Spencer B, Crews L, Adame A, Patrick C, Trejo M, Dallapiccola B, Valente EM, Masliah E (2009) Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of parkinson's disease by disturbing calcium flux. J Neurochem 108, 1561-1574.
69. Wilson MA, Collins JL, Hod Y, Ringe D, Petsko GA (2003) The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc Natl Acad Sci USA 100, 9256-9261.
70. Shang H, Lang D, Jean-Marc B, Kaelin-Lang A (2004) Localization of DJ-1 mRNA in the mouse brain. Neurosci Lett 367, 273-277.
71. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Pet-sko GA, Cookson MR (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 101, 9103-9108.
72. Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, Carter DM, Zhu PP, Stadler J, Chandran J, Klinefelter GR, Blackstone C, Cookson MR (2003) L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 278, 36588-36595.
73. Takahashi-Niki K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H (2004) Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem Biophys Res. Commun 320, 389-397.
74. Galter D, Westerlund M, Carmine A, Lindqvist E, Sydow O, Olson L (2006) LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 59, 714-719.
75. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M (2006) Anatomical localization of leucine-rich repeat kinase 2 mouse brain. Neuroscience 139, 791-794.
76. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. HumMol Gen 16, 1319-1326.
77. Ho C C-Y, Rideout HJ, Ribe E, Troy CM, Dauer WT (2009) The Parkinson's disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurode-generation J Neurosci 29, 1011-1016.
78. Goldberg MS, Fleming SM, Palacino JJ, Capedam C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klap-stein GJ, Gajendiram M, Roth BL, Chesselet MF, Maidment NT, Levine MS, Shen J (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278, 43628-43635.
79. Perez FA, Palmiter RD (2005) Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A 102, 2174-2179.
80. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279, 18614-18622.
81. Chen L, Cagniard B, Mathews T, Jones S, Koh HC, Ding Y, Carvey PM, Ling Z, Kang UJ, Zhuang X (2005) Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280, 21418-21426.
82. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada Y, Costa C, Tong Y, Martella G, Tscherter A, Martins A, Bernardi G, Roth BL, Pothos EN, Calabresi P, Shen J (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial parkinsonism-linked gene DJ-1. Neuron 45, 489-496.
83. Lu X-H, Fleming SM, Meurers B, Ackerson LC, Mortazavi Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet M-F, Yang XW (2009) Bacterial artificial chromosome transgenic mice expressing a truncated mutant Parkin exhibit age-dependent hypokinetic motor deficits, dopamin-ergic neuron degeneration, and accumulation of proteinase K-resistant α-synuclein. J Neurosci 29, 1962-1976.
84. Gispert S, Del Turco D, Garrett L, Chen A, Bernard DJ, Hamm-Clement J, Korf HW, Deller T, Braak H, Auburger Nussbaum RL (2003) Transgenic mice expressing mutant A53T human alphα-synuclein show neuronal dysfunction in the absence or aggregate formation. Mol Cell Neurosci 24, 419-429.
85. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen Schindzielorz A, Okochi M, Leimer U, van der Put-ten H, Probst A, Kremmer E, Kretzschmar HA, Haassm C (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alphα-synuclein in human and transgenic mouse brain. J Neurosci 20, 6365-6373.
86. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL (2002) Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 ^ Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99, 8968-8973.
87. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopamin-ergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
88. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuetzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ (2002) Behavioral and neurochemical effects of wild-type and mutated human alphα-synuclein in transgenic mice. Exp Neurol 175, 35-48.
89. van der Putten H, Wiederhold K-H, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G (2000) Neuropathology in mice expressing human α-synuclein. J Neurosci 20, 6021-6029.
90. Wakamatsu M, Ishii A, Iwata S, Sakagami J, Ukai Y, Ono M, Kanbe D, Muramatsu S-I, Kabayashi K, Iwatsubo T, Yoshi-moto M (2008) Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein. Neurobiol Aging 29, 547-585.
91. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK (2006) Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26, 41-50.
92. Lieberman AR (1971) The axon reaction: a review of the principal features of perikaryal responses to axon injury. Int Rev Neurobiol 14, 49-124.
93. Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, But-terfield DA (2005) Mitochondrial associated metabolic proteins are selectively oxidized in A30P α-synuclein transgenic mice-a model of familial Parkinson's disease. Neurobiol Dis 18, 492-498.
94. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D (2001) Alphα-synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 30, 1163-1170.
95. Tabrizi SJ, Orth M, Wilkinson JM, Taanman JW, Warner TT, Cooper JM, Schapira AH (2000) Expression of mutant alphα-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9, 2683-2689.
96. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM-Y, Ischiropoulos H (2001) Induction of alphα-synuclein aggregation by intracellular nitra-tive insult. J Neurosci 21, 8053-8061.
97. Souza JM, Giasson BI, Chen Q, Lee VM-Y, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable α-synuclein polymers. J Biol Chem 265, 18344-18349.
98. Martin LJ, Liu Z, Chen K, Price AC, Pan Y, Swaby JA, Golden WC (2007) Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp Neurol 500, 20-46.
99. Chen K, Northington FJ, Martin LJ (2010) Inducible nitric oxide synthase is present in motor neuron mitochondria and Schwann cells and contributes to disease mechanisms in ALS mice. Brain Struct Funct 214, 219-234.
100. Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. NEngl J Med 344, 1688-1700.
101. Sathasivam S, Ince PG, Shaw PJ (2001) Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neu-ropathol Appl Neurobiol 27, 257-274.
102. Stephens B, Guiloff RJ, Navarrete R, Newman P, Nikhar N, Lewis P (2006) Widespread loss of neuronal populations in spinal ventral horn in sporadic motor neuron disease. A morphometric study. J Neurol Sci 244, 41-58.
103. Maekawa S, Al-Sarraj S, Kibble M, Landau S, Parnavelas J, Cotter D, Everall I, Leigh PN (2004) Cortical selective vulnerability in motor neurons disease: a morphometric study. Brain 127, 1237-1251
104. Zoccolella S, Santamato A, Lamberti P (2009) Current and emerging treatments for amyotrophic lateral sclerosis. Neu-ropsychiatr Dis Treat 5, 577-595.
105. Kabashi E, Valdmains PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard J-P, Lacomblez L, Pochigaeva K, Salachas F, Pradat P-F, Camu W, Meininger V, Dupre N, Rouleau GA (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40, 572-574.
106. Deng H-X, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung W-Y, Getzoff ED, Hu, P, Herzfeldt B, Roos RP, Warner C, Deng G, Soriano E, Smyth C, Parge HE, Ahmed A, Roses AD, Hallewell RA, Pericak-Vance MA, Siddique T (1993) Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261, 1047-1051.
107. Vance C, Rogelj B, Hortobagyi T, de Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Gane-saligam J, Williams KL, Tripathi V, Saraj S, Al-Chalabi, A, Leigh N, Blair IP, Nicholson G, de Belleroche J, Gallo J-M, Miller CC, Shaw CE (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211.
108. Schymick JC, Talbot K, Traynor GJ (2007) Genetics of amyotrophic lateral sclerosis. Hum Mol Genet 16, R233-R242.
109. Chow CY, Lander JE, Bergren SK, Sapp PC, Grant AE, Jones JM, Everett L, Lenk GM, McKenna-Yasek DM, Weisman LS, Figlewicz D, Brown RH, Meisler MH (2009) Deleterious variants ofFIG4, a phosphoinositade phosphatase, in patients with ALS. Am J Human Gen 84, 85-88.
110. Sasaki S, Iwata M (1999) Ultrastructural changes of synapses of Betz cell in patients with amyotrophic lateral sclerosis. Neurosci Lett 268, 29-32.
111. Menzies FM, Ince PG, Shaw PJ (2002) Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Intl 40, 543-551.
112. Comi GP, Bordoni A, Salani S, Franeschina L, Sciacco, M, Prelle A, Fortunato F, Zeviani M, Napoli L, Bresolin N, Moggio M, Ausenda CD, Taanman JW, Scarlato G (1998) Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann Neurol 43, 110-116.
113. Borthwick GM, Taylo RW, Walls TJ, Tonska K, Taylor GA, Shaw PJ, Ince PG, Turnbull DM (2006) Motor neuron disease in a patient with a mitochondrial tRNAIle mutation. Ann Neurol 59, 570-574.
114. Soong NW, Hinton DR, Cortopassi G, Arnheim N (1992) Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat Genet 2, 318-323.
115. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC (1992) Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet 2, 324-329.
116. Mawrin C, Kirches E, Krause G, Wiedemann FR, Vorwerk CK, Bogerts B, Schildhaus HU, Dietzmann K, Schneider-Stock R (2004) Single-cell analysis of mtDNA levels in sporadic amyotrophic lateral sclerosis. NeuroReport 15, 939943.
117. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reve AK, Perry RP, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson's disease. Nat Genet 38, 515-517.
118. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38, 518-520.
119. Babcock D, Hille B (1998) Mitochondrial oversight of cellular Ca2+ signaling. Curr Opin Neurobiol 8, 398-404.
120. Siklos L, Engelhardt J, Harat Y, Smith RG, Joo F, Appel SH (1996) Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann Neurol 39, 203-216.
121. Zoratti M, Szabo I (1995) The mitochondrial permeability transition. Biochem Biophys Acta 1241, 139-176.
122. Olney JW (1971) Glutamate-induced neuronal necrosis in the infant mouse hypothalamus. An electron microscopic study. J Neuropathol Exp Neurol 30, 75-90.
123. Choi DW (1992) Excitotoxic cell death. J Neurobiol 23, 1261-1276.
124. Choi DW (2005) Cellular defences destroyed. Nature 433, 696-698.
125. Brown MR, Sullivan PG, Geddes JW (2006) Synaptic mitochondria are more susceptible to Ca2+ overload than nonsy-naptic mitochondria. J Biol Chem 281, 11658-11668.
126. Rothstein JD, Martin LJ, Kuncl RW (1992) Decreased gluta-mate transport by brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326, 1464-1468.
127. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38, 73-84.
128. Heath PR, Tomkins J, Ince PG, Shaw PJ (2002) Quantitative assessment of AMPA receptor mRNA in human spinal motor neurons isolated by laser capture microdissection. NeuroRe-port 13, 1753-1757.
129. KwakS, Kawahara Y (2005) Deficient RNA editing of GluR2 and neuronal death in amyotrophic lateral sclerosis. J Mol Med 83, 110-120.
130. Chang DTW, Reynolds IJ (2006) Mitochondrial trafficking and morphology in healthy and injured neurons. Prog Brain Res 80, 241-268.
131. Hansson MJ, Mansson R, Morota S, Uchino H, Kallur T, Sumi T, Ishii N, Shimazu M, Keep MF, Jegorov A, Elmer E (2008) Calcium-induced generation of reactive oxygen species in brain mitochondria is mediated by permeability transition. Free Radic Biol Med 45, 284-294.
132. Bergmann F, Keller BU (2004) Impact ofmitochondrial inhibition on excitability and cytosolic Ca?+ levels in brainstem motoneurones. J Physiol 555, 45-59.
133. Beal MF (2002) Oxidatively modified protein in aging and disease. Free Radic BiolMed 32, 797-803.
134. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, BaikMJ, MacGarvey U, Kowall NW, Brown Jr RH, Beal MF (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69, 2064-2074.
135. Abe K, Pan L-H, Watanabe M, Kato T, Itoyama Y (1995) Induction ofnitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett 199, 152-154.
136. Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown Jr RH (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42, 644-654.
137. Sasaki S, Warita H, Abe K, Iwata M (2001) Inducible nitric oxide synthase (iNOS) and nitrotyrosine immunoreactivity in the spinal cords of transgenic mice with mutant SOD1 gene. JNeuropathol Exp Neurol 60, 839-846.
138. Browne SE, Bowling AC, Baik MJ, Gurney M, Brown Jr RH, Beal MF (1998) Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J Neurochem 71, 281-287.
139. Borthwick GM, Johnson MA, Ince PG, Shaw PJ, Turnbull DM (1999) Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 46, 787-790.
140. Vielhaber S, Kunz D, Winkler K, Wiedemann FR, Kirches E, Feistner H, Heinze HJ, Elger CE, Schubert W, Kunz WS (2000) Mitochondrial DNA abnormalities in skeletal muscle ofpatients with sporadic amyotrophic lateral sclerosis. Brain 123, 1339-1348.
141. Soraru G, Vergani L, Fedrizzi L, D'Ascenzo C, Polo A, Bernazzi B, Angelini C (2007) Activities of mitochondrial complexes correlate with nNOS amount in muscle from ALS patients. Neuropath Appl Neurobiol 33, 204-211
142. Echaniz-Laguna A, Zoll J, Ponsot E, N'Guessan B, Tran-chant C, Loeffler J-P, Lampert E (2006) Muscular mitochon-drial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: a temporal study in man. Exp Neurol 198, 25-30.
143. Martin LJ (1999) Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution ofa programmed cell death mechanism. J Neuropathol Exp Neurol 58, 459-471.
144. Martin LJ, Liu Z (2004) Opportunities for neuroprotection in ALS using cell death mechanism rationales. Drug Discov Today 1, 135-143.
145. Ginsberg SD, Hemby SE, Mufson EJ, Martin LJ (2006) Cell and tissue microdissection in combination with genomic and proteomic profiling. In Neuroanatomical Tract-Tracing 3, Molecules, Neurons, and Systems; Zaborszky L, Wouterlood FG, Lanciego JL, eds. Springer: New York, pp. 109-141.
146. Martin LJ (2000) p53 is abnormally elevated and active in the CNS ofpatients with amyotrophic lateral sclerosis. Neurobiol Dis 7, 613-622.
147. Martin LJ (2001) Neuronal cell death in nervous system development, disease, and injury. Int J Mol Med 7, 455-478.
148. Martin LJ, Kaiser A, Price AC (1999) Motor neuron degeneration after sciatic nerve avulsion in adult rat evolves with oxidative stress and is apoptosis. J Neurobiol 40, 185-201.
149. Martin LJ, Liu Z (2002) Injury-induced spinal motor neuron apoptosis is preceded by DNA single-strand breaks and is p53-and Bax-dependent. J Neurobiol 50, 181-197.
150. Fornai F, Longone P, Ferrucci M, Lenzi P, Isidoro C, Ruggieri S, Paparelli A (2008) Autophagy and amyotrophic lateral sclerosis. Autophagy 4, 527-530.
151. Turner BJ, Talbot K (2008) Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 85, 94-134.
152. McCord JM, Fridovich I (1969) Superoxide dismutase, an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244, 6049-6055.
153. Rakhit, R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabartty A (2004) Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic sclerosis. J Biol Chem 279, 15499-15504.
154. Ferri A, Cozzolino M, Crosio C, Nencini M, Casciati A, Gralla EB, Rotilio G, Valentine JS, Carri MT (2006) Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc Natl Acad Sci U S A 103, 13860-13865.
155. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey L, Barbeito MM, Beckman JS (1999) Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 286, 2498-2500.
156. Flanagan SW, Anderson RD, Ross MA, Oberley LW (2002) Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J Neurochem 81, 170-177.
157. Bilsland LG, Nirmalananthan N, Yip J, Greensmith L, Duh-cen MR (2008) Expression of mutant SOD1G93A in astro-cytes induces functional deficits in motoneuron mitochondria. J Neurochem 107, 1271-1283.
158. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775.
159. Dal Canto MC, Gurney ME (1994) Development of central nervous system
160. Martin LJ, Gertz B, Pan Y, Price AC, Molkentin JD, Chang Q (2009) The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Exp Neurol 218, 33-346.
161. Chang Q, Martin LJ (2009) Glycinergic innervation of mo-toneurons is deficient in amyotrophic lateral sclerosis mice: aconfocal quantitative analysis. Am J Pathol 174, 574-585.
162. Bendotti C, Calvaresi N, Chiveri L, Prelle A, Moggio M, BragaM, Silani V, De Biasi S (2001) Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J Neurol Sci 191, 25-33.
163. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14, 1105-1116.
164. Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 18, 3241-3250.
165. Jaarsma D, Rognoni F, van Duijn W, Verspaget HW, Haasdijk ED, Holstege JC (2001) CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol 102, 293-305.
166. Sasaki S, Warita H, Murakami T, Abe K, Iwata M (2004) Ultrastructural study of mitochondria in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol 107, 461-474.
167. Borchelt DR, Lee MK, Slunt HH, Guarnieri M, Xu Z-S, Wong PC, Brown Jr R.H, Price DL, Sisodia SS, Cleveland DW (1994) Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA 91, 8292-8296.
168. Yim MB, Kang J-H, Yim H-S, Kwak H-S, Chock PB, Stadt-man ER (1996) A gain-of-function of an amyotrophic lateral sclerosis-associated Cu, Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci U SA 93, 5709-5714.
169. Kabashi E, Valdmanis PN, Dion P, Rouleau GA (2007) Ox-idized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann Neurol 62, 553-559.
170. Ezzi SA, Urushitani M, Julien J-P (2007) Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem 102, 170-178.
171. Liochev SI, Fridovich I (2003) Mutant Cu,Zn superoxide dis-mutases and familial amyotrophic lateral sclerosis: evaluation of oxidative hypotheses. Free Radic Biol Med 34, 13831389.
172. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87, 315-424.
173. Andrus PK, Fleck TJ, Gurney ME, Hall ED (1998) Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 71, 2041-2048.
174. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, Klein JB, Calabrese V, Butterfield DA (2005) Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 39, 435-462.
175. Okado-Matsumoto A, Fridovich I (2001) Subcellular distribution of superoxide (SOD) in rat liver. J Biol Chem 276, 38388-38393.
176. Higgins CMJ, Jung C, Ding H, Xu Z (2002) Mutant Cu, Zn Superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci 22, RC215:1-6.
177. Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, Trotti D, Brown Jr RH (2004) Amyotrophic lateral sclerosis-associated SOD1 mutant protein bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43, 19-30.
178. Vande Velde C, Miller TM, Cashman NR, Cleveland DW (2008) Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc Natl Acad Sci USA 105, 4022-4027.
179. Goldsteins G, Keksa-Goldsteine V, Ahtiniemi T, Jaronen M, Arens E, Akerman K, Chan RH, Koistinaho J (2008) Deleterious role of superoxide dismutase in the mitochondrial intermembrane space. J Biol Chem 283, 8446-8452.
180. Higgins CM, Jung C, Xu Z (2003) ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 4, 16.
181. De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau K-F, Browlees J, Ackerley S, Shaw PJ, McLoughlin DM, Shaw CE, Leigh PN, Miller CCJ, Grierson AJ (2007) Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondrial content. Hum Mol Genet 16, 2720-2728.
182. Martin LJ, Chen K, Liu Z (2005) Adult motor neuron apopto-sis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. J Neurosci 25, 64496459.
183. Siklos L, Engelhardt JI, Alexianu ME, Gurney ME, Siddique T, Appel SH (1998) Intracellular calcium parallels motoneu-ron degeneration in SOD-1 mutant mice. J Neuropath Exp Neurol 57, 571-587.
184. Jaiswal MK, Keller BU (2009) Cu/Zn superoxide dismutase typical for familial amyotrophic lateral sclerosis increases the vulnerability of mitochondria and perturbs Ca?+ homeostasis in SOD1G93A mice. Mol Pharmacol 75, 478-489.
185. Nguyen KT, Garcia-Chacon LE, Barrett JN, Barrett EF, David G (2009) The m depolarization that accompanies mitochondrial Ca2+ uptake is greater in mutant SOD1 than in wild-type mouse motor terminals. Proc Natl Acad Sci USA 106, 2007-2011.
186. Sasaki S, Shibata N, Komori T, Iwata M (2000) iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Neurosci Lett 291, 44-48.
187. Martin LJ (2010) Mitochondrial and cell death mechanisms in neurodegenerative diseases. Pharmaceuticals 3, 839-915.
188. Kunz WS (2003) Different metabolic properties of mitochondrial oxidative phosphorylation in different cell types-important implications for mitochondrial cytopathies. Exp Physiol 88, 149-154.
189. Keep M, Elmer E, Fong KSK, Csiszar K (2001) Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res 894,27-331.
190. Karlsson J, Fong KS, Hansson MJ, Elmer E, Csiszar K, Keep MF (2004) Life span extension and reduced neuronal death after weekly intraventricular cyclosporine injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. JNeurosurg 101, 128-137.
191. Kirkinezos IG, Hernandez, Bradley WG, Moraes CT (2004) An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J Neu-rochem 88, 821-826.
192. Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P, Akentieva NP, Evers AS, Covey DF, Ostuni MA, lacapere JJ-J, Massaad C, Schmacher M, Steidl E-M, Maux D, De-laage M, Henderson CE, Pruss RM (2007) Identification and characterization of Cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 322, 709-720.
193. Mills C, Makwana M, Wallace A, Benn S, Schmidt H, Tegeder I, Costigan M, Brown Jr RH, Raivich G, Woolf C (2008) Ro5-4864 promotes neonatal motor neuron survival and nerve regeneration in adult rats. Eur J Neurosci 27, 937946.
194. Yan L-J, Sohal RS (1998) Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. Proc Natl Acad Sci USA 95, 12896-12901.
195. Prokai L, Yan L-J, Vera-Serrano JL, Stevens Jr SM, Forster MJ (2007) Mass spectrometry-based survey of age-associated protein carbonylation in rat brain mitochondria. J Mass Spectrom 42, 1583-1589.
196. Vieira HLA, Belzacq A-S, Haouzu D, Bernassola F, Cohen I, Jacotot E, Ferri KF, Hamel CE, Bartle LM, Melino G, Brenner C, Goldmacher V, Kroemer G (2001) The adenine nucleotide translocator: a target ofnitric oxide, peroxynitrite, and 4-hydroxynonenal. Oncogene 20, 4305-4316.
197. McStay GP, Clarke SJ, Halestrap AP (2002) Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem J 367, 541-548.
198. Costantini P, Belzacq A-S, Vieira HLA, Larochette N, de Pablo MA, Zamzami N, Susin SA, Brenner C, Kroemer G (2000) Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 19, 307-314.
199. Garcia N, Martlnez-Abundis E, Pavon N, Correa F, Chavez E (2007) Copper induces permeability transition through its interaction with the adenine nucleotide translocase. Cell Biol Int 31, 893-899.
200. Grimm S, Brdiczka D (2007) The permeability transition pore in cell death. Apoptosis 12, 841-855.
201. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Aranico O, Chen JX, Yan SD (2008) Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14, 1097-1105.
202. Forte M, Gold BG, Marracci G, Chaudhary P, Basso E, Johnsen D, Yu Z, Fowlkes J, Rahder M, Stern K, Bernardi P, Bourdette D (2007) Cyclophilin D inactivation protects ax-ons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc Natl Acad Sci U S A 104, 7558-7563.
203. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hertz C, Danial NN, Moskowitz MA, Korsmeyer SJ (2005) Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. ProcNatlAcadSci USA 102, 1200512010.
204. Gordon PH, Moore DH, Miller RG, Florence JM, Verhei-jde JL, Doorish C, Hilton JF, Spitalny GM, MacAuthur RB, Misumoto H, Neville HE, Biylan K, Mozaffar T, Belch JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R (2007) Efficacy ofminocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol 6, 1045-1053.
205. Wong M, Martin LJ (2010) Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet 19, 2284-2302.